Xencor (XNCR) Long-Term Investments (2015 - 2026)
Xencor's (XNCR) quarterly Long-Term Investments came in at $157.4 million in Q1 2026, down 42.31% year-on-year from $272.8 million in Q1 2025, and down 10.37% on a QoQ basis from $175.6 million in Q4 2025.
Xencor (XNCR) Long-Term Investments (2015 - 2026) Analysis & Trends
Xencor (XNCR) has 12 years of Long-Term Investments data on file, last reported at $157.4 million in Q1 2026.
- On a quarterly basis, Long-Term Investments fell 42.31% year-over-year to $157.4 million in Q1 2026; TTM through Mar 2026 was $157.4 million, a 42.31% decrease from a year earlier, with the FY2025 full-year figure at $175.6 million, down 31.63% from the prior year.
- Long-Term Investments for Q1 2026 stood at $157.4 million, down from $175.6 million in the prior quarter.
- Over the last five years, Long-Term Investments for XNCR reached as high as $290.3 million in Q3 2024 and fell as low as $31.1 million in Q2 2022.
- Historically, Long-Term Investments has averaged $130.8 million across 5 years, with a median of $64.2 million in 2023.
- Across the five-year window, Long-Term Investments slumped 88.75% in 2022 and soared 526.3% in 2025, its largest moves.
- Year by year, Long-Term Investments stood at $54.4 million in 2022, then soared by 167.57% to $145.5 million in 2023, then surged by 76.5% to $256.8 million in 2024, then tumbled by 31.63% to $175.6 million in 2025, then dropped by 10.37% to $157.4 million in 2026.
- Per Business Quant data, the three most recent Long-Term Investments figures were $157.4 million in Q1 2026, $175.6 million in Q4 2025, and $247.2 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,561.01 Bn | 66,560.72 Bn | - | - |
| 2 | Nanobiotix | 1,912.79 Bn | 1,912.72 Bn | - | 505,194.89 |
| 3 | Akari Therapeutics | 1,045.06 Bn | 1,045.06 Bn | - | - |
| 4 | BeOne Medicines | 469.79 Bn | 465.00 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 122.95 Bn | 115.70 Bn | 2.59 Bn | 5.75 Bn |
| 6 | Regeneron Pharmaceuticals | 70.05 Bn | 61.30 Bn | 3.31 Bn | 9.79 Bn |
| 7 | Belite Bio | 62.62 Bn | 62.62 Bn | - | - |
| 8 | Argenx Se | 56.18 Bn | 50.99 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Xencor | 1.49 Bn | 1.10 Bn | - | 157.39 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 157.39 Mn |
| Dec 31, 2025 | 175.60 Mn |
| Sep 30, 2025 | 247.16 Mn |
| Jun 30, 2025 | 260.40 Mn |
| Mar 31, 2025 | 272.82 Mn |
| Dec 31, 2024 | 256.83 Mn |
| Sep 30, 2024 | 290.27 Mn |
| Jun 30, 2024 | 43.78 Mn |
| Mar 31, 2024 | 43.56 Mn |
| Dec 31, 2023 | 145.51 Mn |
| Sep 30, 2023 | 64.21 Mn |
| Jun 30, 2023 | 64.21 Mn |
| Mar 31, 2023 | 54.21 Mn |
| Dec 31, 2022 | 54.38 Mn |
| Sep 30, 2022 | 31.12 Mn |
| Jun 30, 2022 | 31.12 Mn |
| Mar 31, 2022 | 31.26 Mn |
| Dec 31, 2021 | 31.26 Mn |
| Sep 30, 2021 | 276.74 Mn |
| Jun 30, 2021 | 153.62 Mn |